Atherosclerosis Drugs Market to Grow with a CAGR of 3.21% through 2030
Rising prevalence of atherosclerosis and expanding geriatric
population are factors driving the global Atherosclerosis Drugs market in the forecast
period 2026-2030.
According to TechSci Research report, “Atherosclerosis
Drugs Market – Global Industry Size, Share, Trends, Competition Forecast
& Opportunities, 2030”, the Global Atherosclerosis Drugs Market swas
valued at USD 18.85 Billion in 2024 and is expected to reach USD 22.84 Billion by
2030 with a CAGR of 3.21% during the forecast period. Atherosclerosis,
a chronic disease characterized by the accumulation of fatty deposits in the
arteries, remains a significant global health concern. It is a leading cause of
heart attacks, strokes, and other cardiovascular diseases, resulting in
millions of deaths each year. The global atherosclerosis drugs market plays a
crucial role in addressing this health issue, and its growth and dynamics are
influenced by several market drivers. One of the primary market drivers for
atherosclerosis drugs is the increasing prevalence of the disease. Sedentary
lifestyles, poor dietary habits, and a rise in risk factors such as obesity,
diabetes, and hypertension have contributed to the growing incidence of
atherosclerosis. As more people are diagnosed with this condition, there is a
greater demand for effective treatments, driving the market for atherosclerosis
drugs.
The global demographic shift toward an aging population is another crucial driver of the atherosclerosis drugs market. Atherosclerosis is more common in older individuals, and as the elderly population grows, so does the pool of potential patients. This demographic trend creates a sustained demand for drugs that can manage atherosclerosis and its associated complications. Advancements in pharmaceutical research and development have led to the discovery of innovative drugs and therapies for atherosclerosis. These new treatments target various aspects of the disease, such as reducing cholesterol levels, managing blood pressure, and addressing inflammation. Technological progress in drug development has expanded the therapeutic options available to healthcare providers, offering better outcomes for patients and driving market growth.
Efforts to raise awareness about cardiovascular diseases, including atherosclerosis, have resulted in more individuals seeking regular check-ups and screenings. Early detection of atherosclerosis enables prompt intervention, often involving the use of pharmaceuticals. As public awareness grows, there is a corresponding increase in the demand for atherosclerosis drugs. Health-conscious individuals are increasingly adopting lifestyle modifications to prevent or manage atherosclerosis. These changes include healthier diets, regular exercise, and smoking cessation. While lifestyle modifications are essential for disease prevention, they are often complemented by pharmaceutical interventions. The market for atherosclerosis drugs benefits from individuals proactively addressing their risk factors.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Global Atherosclerosis Drugs Market”
The Global Atherosclerosis Drugs Market is segmented into
diagnosis, treatment, route of administration, end user, region and company.
Based on end user, The Hospitals & Clinics segment is projected to be the fastest-growing segment during the forecast period. These healthcare institutions are critical in the diagnosis, treatment, and management of atherosclerosis, making them pivotal in the fight against cardiovascular diseases. With a growing aging population and increasing awareness of heart-related conditions, hospitals and clinics are seeing a surge in patients seeking early detection and treatment for atherosclerosis through advanced diagnostic techniques like angiography, ultrasound, and CT scans. As the demand for personalized and immediate care rises, hospitals are expanding their treatment offerings, including innovative medications and cutting-edge surgical procedures like angioplasty and coronary artery bypass grafting (CABG). Additionally, with more focus on post-treatment care, rehabilitation programs that emphasize lifestyle changes, exercise, and dietary counseling are becoming integral in preventing further disease progression. The ongoing rise in chronic cardiovascular conditions, along with the growing adoption of atherosclerosis management programs, positions hospitals and clinics as the fastest-growing sector in the healthcare landscape..
Based on region, Europe was the
second dominant market in the global atherosclerosis drugs sector. Europe’s
strong position in this market is primarily attributed to its well-established
healthcare infrastructure, advanced medical technology, and high awareness of
cardiovascular diseases, particularly atherosclerosis. As the prevalence of
lifestyle-related diseases such as hypertension, diabetes, and obesity
continues to rise, the demand for effective atherosclerosis treatments has
surged in this region. Europe’s extensive healthcare system, which includes
universal healthcare coverage in many countries, also plays a critical role in
ensuring broader access to treatment for patients with atherosclerosis. The European
market benefits from a large number of pharmaceutical companies and a strong
research and development (R&D) sector that focuses on cardiovascular
disease therapies, including those for atherosclerosis. The region is home to
numerous major global pharmaceutical companies that are engaged in the
development and commercialization of new drugs for treating atherosclerosis.
Furthermore, there is a significant amount of funding and investment directed
towards the cardiovascular research space in Europe, which enables the
development of innovative atherosclerosis treatments. Governmental
health policies in Europe have also been crucial in driving the demand for
atherosclerosis medications. With a focus on reducing the burden of
cardiovascular diseases, many European governments have implemented national
programs and guidelines to promote early diagnosis and treatment of
atherosclerosis. In addition, public health campaigns aimed at preventing the
risk factors associated with atherosclerosis, such as smoking, poor diet, and
lack of exercise, are integral parts of health policies in countries across
Europe. These efforts contribute to increasing awareness of the condition and
its potential complications, thereby driving demand for effective drugs.
Moreover, the
region’s aging population further fuels the market for atherosclerosis drugs.
Europe has one of the highest proportions of elderly citizens in the world, and
this demographic is more susceptible to conditions such as atherosclerosis due
to the natural aging of blood vessels and increased prevalence of comorbidities
like diabetes and hypertension. The rise in age-related cardiovascular diseases
is expected to drive a greater need for atherosclerosis treatments,
particularly for medications targeting lipid profiles, blood pressure
regulation, and other factors associated with the disease.
Major companies operating in Global Atherosclerosis
Drugs Market are:
- F. Hoffmann-La Roche Ltd
- Novartis AG
- Merck & Co. Inc.
- Pfizer Inc.
- Eli Lilly and Co.
- Sanofi S.A.
- AstraZeneca Plc
- Bayer AG
- Regeneron Pharmaceuticals Inc.
- GSK Plc
Download Free Sample Report
Customers can also request for 10%
free customization on this report
“The future of the global atherosclerosis
drugs market looks promising, driven by advancements in treatment options and
increasing demand due to the rising prevalence of cardiovascular diseases. As
research continues to progress, new drug classes targeting cholesterol, blood
pressure, and inflammation are expected to emerge, providing more effective
solutions for managing atherosclerosis. Additionally, the aging population,
particularly in developed regions like Europe and North America, will
contribute to market growth as the risk of atherosclerosis increases with age.
Regulatory support for cardiovascular disease treatments, coupled with a
growing focus on preventative care, will further boost market expansion. The
shift towards personalized medicine and combination therapies will also offer
more tailored and efficient treatments for patients, enhancing long-term market
potential”, said Mr. Karan Chechi,
Research Director of TechSci Research, a research-based management consulting
firm.
“Atherosclerosis Drugs Market
- Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Diagnosis
(Ankle-brachial Index, Doppler Ultrasound, Echocardiogram, Electrocardiogram,
Blood Tests, Others), By Treatment (Medication, Surgery, Others), By Route of
Administration (Oral, Parenteral, Others), By End User (Hospitals &
Clinics, Ambulatory Care Centers, Others), By Region and Competition,
2020-2030F”, has evaluated
the future growth potential of Global Atherosclerosis Drugs Market and provides
statistics & information on market size, structure and future market
growth. The report intends to provide cutting-edge market intelligence and help
decision makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Atherosclerosis Drugs Market.
Contact
TechSci
Research LLC
420
Lexington Avenue, Suite 300,
New
York, United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com